Q-omics provides the consensus-scored ZNF625-ZNF20 profile across patient tissues and cancer cell-line models. ZNF625-ZNF20 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF625-ZNF20 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, ZNF625-ZNF20 RNA expression shows 17,731 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where ZNF625-ZNF20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF625-ZNF20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF625-ZNF20 survival associations across molecular data types. ZNF625-ZNF20 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF625-ZNF20 RNA expression–survival associations across cancer types. High ZNF625-ZNF20 expression shows unfavorable associations in COAD, LUSC, UVM and LGG, but favorable associations in KIRC and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF625-ZNF20 RNA expression.
This table summarizes ZNF625-ZNF20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF625-ZNF20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF625-ZNF20 shows lower tumor expression in THCA, KICH, COAD and KIRC and higher tumor expression in LIHC and BLCA. The THCA box plot shows higher ZNF625-ZNF20 RNA expression in normal versus tumor tissue (log2 FC = −0.114, t-test p < 0.001).
This table shows molecular features associated with ZNF625-ZNF20 in patient tissues and cancer cell lines. In patient samples, ZNF625-ZNF20 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF625-ZNF20 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN.
